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Background: Chlamydia trachomatis (C. trachomatis) is the most common bacterial sexually transmitted infection (STI). Although most genital C. trachomatis infections remain asymptomatic but infection with these bacteria is the leading cause of complications, such as pelvic inflammatory disease (PID), tubal factor infertility and abortion.
Objectives: The objective of this study was to estimate the frequency of C. trachomatis infection among symptomatic and asymptomatic women, by a polymerase chain reaction (PCR) based assay.
Patients and Methods: This was a cross-sectional study conducted over the period from May 2012 to February 2013. A total of 240 non-duplicate endocervical samples were taken from married women; endocervical swabs were collected from women referred to Qazvin Kowsar Gynecology Hospital by a training midwife. The specimens were tested for C. trachomatis by a PCR-based assay for the pha gene.
Results: Out of the 240 female participants, 184 (76.7%) were symptomatic and 56 (23.3%) were asymptomatic cases. The mean age of cases was 37.1 ± 0.9 years. Twenty (8.3%) of the 240 samples were diagnosed as Chlamydia positive according to PCR results. The prevalence of asymptomatic C. trachomatis infections was six (10.7%), while there were 14 (7.6%) in symptomatic cases. Although positive PCR results have shown in women with vaginosis (7.1%), abortion (5.1%), premature birth and low birth weight below 2.5 kg (7.7%) but the chi-square test did not indicate a significant relationship between positive PCR test results and these symptoms.
Conclusions: The results of this study showed that there was a high prevalence of C. trachomatis infection among both symptomatic and asymptomatic women. Therefore, a screening test for C. trachomatis infection is recommended for all women who refer to the genitourinary medicine clinic. Screening programs are important for cost effectiveness calculations of C. trachomatis infections especially in asymptomatic cases.
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1. BackgroundChlamydia trachomatis (C. trachomatis) is an obligate intra-cellular pathogen and the most frequent sexually transmitted bacterium worldwide (1-4). Most infections occur without symptoms and asymptomatic manifesta-tion of urogenital chlamydial infection can be observed in ~30% of patients. Although effective antimicrobial therapy is available for C. trachomatis, yet undetected and untreat-ed infections lead to diseases such as salpingitis, pelvic inflammatory disease (PID), tubal infertility and abortion (5-9). Chlamydia trachomatis in the cervix could be trans-mitted to a neonate during passage through an infected birth canal, resulting in neonatal pneumonia (6, 10).The gold standard for diagnosis of C. trachomatis infec-tion has traditionally been a culture of swab from the en-docervix in women or the urethra in men (6). However, the methodological challenges of culturing of this organism 
and difficulty of this method have led to the development of non-culture-based tests, including antigen-detection tests and nucleic acid hybridization. These techniques however, fail to detect a substantial proportion of infec-tions. Newer tests are accordingly required to be devel-oped that could amplify and detect C. trachomatis-specific DNA or RNA sequences, with greater sensitivity than first generation non-culture-based tests (10-14). In many stud-ies, the target gene for nucleic acid amplification tests (NAATs) has been the cryptic plasmid. Some studies give evidence or suggest that plasmid-free variants are present in clinical samples. Thus, infections caused by plasmid-free variants will be undetected if the plasmid is used as the target gene (12). Targets for amplification have in-cluded both cryptic plasmid (7, 8, 10, 18, 19, 22 - 24, 27) and chromosomal genes, including those for the major outer 
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membrane protein (MOMP) (2, 11, 23, 25, 33), gyrA and phos-pholipase D endonuclease superfamily gene (PRPHA).
2. ObjectivesThe objective of this study was to estimate the frequen-cy of C. trachomatis infection among symptomatic and asymptomatic women, by a polymerase chain reaction (PCR)-based assay using unique sequences (15).
3. Patients and MethodsThis was a cross-sectional study conducted over the pe-riod from May 2012 to February 2013. During a ten-month-period, 240 endocervical samples were taken from mar-ried women, who had referred to Kowsar Gynecology Hospital Qazvin, by a training midwife. The patient’s de-mographic data and medical histories were collected by direct interviews and completion of the questionnaire.
3.1. Sample CollectionBriefly, cervical mucus was removed prior to insertion of a Dacron swab into the endocervical canal; the swab was then immersed in 1 mL of phosphate buffered saline (PBS) transport medium. All PBS media were maintained at 4ºC during specimen collection and then aliquoted into DN-ase and RNase free microtubes and frozen at -80ºC within four hours of collection until DNA extraction (16).
3.2. DNA ExtractionDNA was extracted from endocervical samples using the boiling technique by DNG PLUS (CinnaGen, Iran). The concentration of DNA samples was determined as micro-grams per milliliter based on A260 values and adjusted to 1 µL/mL prior to PCR amplification. All extracted DNA were stored at -20ºC until analysis by PCR.
3.3. Detection of Chlamydia trachomatis by PCRPCR assay was performed for detection of C. trachomatis by the pha gene. The primers were F-(5’TCTTTTTAAACCTCCGGAACCCACTT3’) and R-(5’GGATGGCATCGCATAGCATTCTTTG3’). The PCR product size was 378 bp. PCR amplifica-tion was performed in a final volume of 20 µL, contain-ing 1 µL of each primer (10 pmol/µL, 10 µL master mix sybr green (Bioneer-USA)), 6 µL of distilled water and 2 µL of DNA samples. Sequenced C. trachomatis DNA was used as the positive control and distilled water was used as the negative control. DNA amplification was carried out with the following thermal cycling profile for pha gene; 10 minutes of initial denaturation at 95ºC followed by 35 cycles of amplification. Each cycle consisted of dena-turation at 95ºC for 15 seconds, annealing at 60ºC for 30 seconds, and extension at 72ºC for 30 seconds. The PCR products were analyzed by 1.5% agarose gel electropho-resis and the product size was estimated using a 100 bp DNA ladder (Fermentas).
3.4. Statistical AnalysesData Statistical analysis was performed using the Sta-tistical Package for the Social Sciences software (SPSS) (version 19.0; SPSS Inc, Chicago, IL, USA). Data were sum-marized by frequencies and percentages for categorical variables and by means and standard deviations for nor-mally distributed data. The relationship between results was analyzed by chi-square tests. A P value of < 0.05 was considered as statistically significant.
4. ResultsThe study population consisted of 240 married women; 184 (76.7%) symptomatic and 56 (23.3%) asymptomatic cases. The mean age of cases was 37.1 ± 0.9 years. During the period of this study, 240 married women with various complications were enrolled, including: 18 (7.5%) infertil-ity, 58 (24.16%) abortion, 126 (52.5%) vaginosis (signs and symptoms included vaginal discharge, vaginal irritation and dysuria), 13 (5.4%) premature birth, 15 (6.25%) and low birth weight below 2.5 kg. Out of the 240 endocervical swab samples, 20 (8.3%) were positive for C. trachomatis by PCR of pha gene (Figure 1). Of the 56 asymptomatic women, six (10.7%) had chlamydia infection while among the 184 symptomatic cases 14 (7.6%) had this infection, ac-cording to the PCR results.Among symptomatic women with chlamydial infec-tion, infertility was not present in any of the cases (0%), while abortion was present in three (5.1%), vaginosis in nine (7.1%) premature birth in one (7.7%) and low birth weight in one (7.7%).The chi-square test was used to evaluate the relation-ship between symptoms of genital infection using PCR. None of the symptoms such as genital discharge, dysuria, genital itching (vaginosis), abortion, premature birth, low birth weight (below 2.5 kg) and infertility showed a significant association with the infection (Table 1).
Figure 1. Detection of Chlamydia trachomatis From Endocervical Swab Specimens by PCR Using pha Gene Primers
100 bp DNA ladder L2, L4: negative clinical sample; L1, L3: positive clinical sample; L5: sequenced positive control
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Table 1.  Frequency of Chlamydia trachomatis in Endocervical Specimens of Married Women According to Symptomsa
Characteristic PCR Positive PCR Negative Total P Value
SymptomaticInfertility 0 (0) 18 (100) 18 (100) 0.36Abortion 3 (5.1) 55 (94.9) 58 (100) 0.55Vaginosis 9 (7.1) 117 (92.9) 126 (100) 076Premature birth 1 (7.7) 12 (92.3) 13 (100) 1.0Low birth weight below 2.5 kg 1 (7.7) 12 (92.3) 13 (100) 1.0
AsymptomaticHealthy women 6 (10.7) 50 (89.3) 56 (100)a Data are presented as No. (%).
5. DiscussionUrogenital C. trachomatis infection has become a ma-jor public health problem world-wide and is one of the most frequent causes of sexually transmitted diseases (1, 2). It is a common cause of urethritis and cervicitis. Some reported sequelae include PID, abortion, tubal factor infertility, epididymitis, proctitis and reactive arthritis (5-9). The majority of chlamydia-infected individuals are asymptomatic, and remain unnoticed and untreated. In-fected women may be at risk of gynaecological compli-cations (e.g. PID and tubal infertility), and determine the reservoir for onward transmission in the population (17).In the current study, the prevalence of C. trachomatis in-fection among 240 women attending Kowsar Gynecology Hospital in Qazvin was 8.3%; six cases were asymptomatic (10.7%), while 14 (7.6%) were symptomatic. The chi-square test did not show a significant relationship between posi-tive test results and vaginosis, abortion, premature birth, low birth weight below 2.5 kg and infertility.Torrone et al. (18) reported that the prevalence of C. tra-chomatis genital infection among people aged 14-39 years in the United States was 1.7%, during 2007-2012. Overall the prevalence of chlamydial infection among individu-als aged 14-39 years was similar over the three National Health and Nutrition Examination Survey (NHANES) cycles combined for this analysis: 2007-2008: 1.6% (CI = 1.1-2.2%); 2009 - 2010: 1.7% (CI = 1.2-2.1%); and 2011-2012: 1.9% (CI = 1.5-2.2%). Chlamydia is the most commonly reported nationally notifiable disease, with over 1.4 million infec-tions reported in 2012. However, case reports commonly underestimate the burden of this disease because most infections are asymptomatic and are neither diagnosed nor reported. The 2007-2012 NHANES indicated that an es-timated 1.8 million people aged 14-39 years in the United States have a genital chlamydial infection. These results showed increasing rates of chlamydial infection during 2007-2012 in the USA (18). Based on several investigations, prevalence of C. trachomatis infection varies with differ-ent populations and the type and sensitivity of the detec-tion methods used.
Marcone et al. (19) reported the prevalence of C. tracho-matis infection of women in Rome. The mean prevalence of C. trachomatis endocervical infection during 2000 to 2009 was 5.2%. The results of this study showed a high rate for sexually transmitted infections (STI). Al-Thani et al. (9) reported the prevalence of C. trachomatis infection among 377 (37.9% Qataris and 62.1% non-Qataris) healthy women attending primary healthcare centers in Qatar. The specimens were tested for C. trachomatis by a PCR-based assay. Prevalence of C. trachomatis infection was 5.3% among Qatari women and 5.5% among non-Qatari women. Similar to our study, this high prevalence may reflect, in part, the limited access to and use of chlamyd-ia screening and management (9). Araujo et al. (20) in central Brazil reported that the overall prevalence of C. trachomatis infection by PCR was 19.6%. Cuffini et al. (21) reported that the prevalence of genital C. trachomatis in-fection in asymptomatic women in Argentine was 13.7%. Their results showed higher prevalence of C. trachomatis infection among Latin-American women than our study.The present study showed that C. trachomatis endocer-vical infection could be present in symptomatic (7.6%) as well as asymptomatic women (10.7%). The majority of chlamydia-infected individuals were asymptomatic, and remained undetected, unnoticed and untreated. Infect-ed women may be at risk of gynecological complications (e.g. PID and tubal infertility), and determine the reser-voir for onward transmission in the population. Strate-gies for the control of infection and prevention of its complications are only partially effective because there is no available vaccine while there is high-risk sexual behav-ior in the population. Screening programs have been in-troduced as an additional strategy for early detection and treatment of infected cases. Cost-effectiveness of screen-ing is largely determined by the rates of complications prevented. Nucleic acid amplification methods, such as PCR, have high sensitivity, specificity and require a short duration of time for obtaining results, therefore are pre-ferred for diagnosis of chlamydial infection.
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